SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Prempro Tablets

Trade Name:	PREMPRO, PREMIA, PREMELLE
Synonyms:	Conjugated Estrogens and Medroxyprogesterone Acetate Tablets
Chemical Family:	Steroid

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used for hormone replacement therapy

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 1A
Carcinogenicity: Category 1A

Label Elements

Signal Word: Danger

Hazard Statements:
H350 - May cause cancer
H360FD - May damage fertility. May damage the unborn child.

Precautionary Statements:
P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

Other Hazards An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Calcium sulfate	7778-18-9	231-900-3	Not Listed	*
Conjugated estrogens	12126-59-9	235-199-5	Carc.1A (H350) Repr.1A (H360FD)	0.5
Magnesium stearate	557-04-0	209-150-3	Not Listed	*
Medroxyprogesterone acetate	71-58-9	200-757-9	Carc. 2 (H351) Repr. 1A (H360FD)	2.5
Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	*
Polyethylene glycol	25322-68-3	Not Listed	Not Listed	*
Sucrose	57-50-1	200-334-9	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Povidone	9003-39-8	Not Listed	Not Listed	*
Tricalcium Phosphate	7758-87-4	231-840-8	Not Listed	*
Ethyl Acrylate and Methyl Methacrylate Copolymer Dispersion - NF	9010-88-2	Not Listed	Not Listed	*
Glyceryl oleate	25496-72-4	247-038-6	Not Listed	*
Hydroxypropyl cellulose	9004-64-2	Not Listed	Not Listed	*
Hydroxypropyl methylcellulose	9004-65-3	Not Listed	Not Listed	*
Lactose NF, monohydrate	64044-51-5	Not Listed	Not Listed	*
Methylcellulose	9004-67-5	Not Listed	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Rinse thoroughly with plenty of water, also under the eyelids. If irritation occurs or persists, get medical attention.

Skin Contact: Wash off immediately with soap and plenty of water If irritation occurs or persists, get medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

7. HANDLING AND STORAGE

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Calcium sulfate

ACGIH Threshold Limit Value (TWA)	10 mg/m^3
Australia TWA	10 mg/m^3
Austria OEL - MAKs	5 mg/m^3
Belgium OEL - TWA	10 mg/m^3
Bulgaria OEL - TWA	10.0 mg/m^3
France OEL - TWA	10 mg/m^3
Germany - TRGS 900 - TWAs	6 mg/m^3
Germany (DFG) - MAK	1.5 mg/m^3 4 mg/m^3
Hungary OEL - TWA	6 mg/m^3
Ireland OEL - TWAs	10 mg/m^3
Latvia OEL - TWA	4 mg/m^3
OSHA - Final PELS - TWAs:	15 mg/m^3
Portugal OEL - TWA	10 mg/m^3
Slovakia OEL - TWA	6 mg/m^3
Slovenia OEL - TWA	6 mg/m^3
Spain OEL - TWA	10 mg/m^3
Switzerland OEL -TWAs	3 mg/m^3

Conjugated estrogens

Pfizer OEL TWA-8 Hr:	0.15µg/m^3

Magnesium stearate

Lithuania OEL - TWA	5 mg/m^3
Sweden OEL - TWAs	5 mg/m^3

Medroxyprogesterone acetate

Pfizer OEL TWA-8 Hr:	2 µg/m^3, Skin

Microcrystalline cellulose

ACGIH Threshold Limit Value (TWA)	10 mg/m^3
Australia TWA	10 mg/m^3
Belgium OEL - TWA	10 mg/m^3
Estonia OEL - TWA	10 mg/m^3
France OEL - TWA	10 mg/m^3
Ireland OEL - TWAs	10 mg/m^3 4 mg/m^3

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Latvia OEL - TWA	2 mg/m^3
OSHA - Final PELS - TWAs:	15 mg/m^3
Portugal OEL - TWA	10 mg/m^3
Romania OEL - TWA	10 mg/m^3
Russia OEL - TWA	6 mg/m^3
Spain OEL - TWA	10 mg/m^3
Switzerland OEL -TWAs	3 mg/m^3
Vietnam OEL - TWAs	10 mg/m^3 5 mg/m^3

Polyethylene glycol

Austria OEL - MAKs	1000 mg/m^3
Germany - TRGS 900 - TWAs	1000 mg/m^3
Germany (DFG) - MAK	1000 mg/m^3 average molecular weight 200-600
Slovakia OEL - TWA	1000 mg/m^3
Slovenia OEL - TWA	1000 mg/m^3
Switzerland OEL -TWAs	1000 mg/m^3

Sucrose

ACGIH Threshold Limit Value (TWA)	10 mg/m^3
Australia TWA	10 mg/m^3
Belgium OEL - TWA	10 mg/m^3
Bulgaria OEL - TWA	10.0 mg/m^3
Estonia OEL - TWA	10 mg/m^3
France OEL - TWA	10 mg/m^3
Ireland OEL - TWAs	10 mg/m^3
Latvia OEL - TWA	5 mg/m^3
Lithuania OEL - TWA	10 mg/m^3
OSHA - Final PELS - TWAs:	15 mg/m^3
Portugal OEL - TWA	10 mg/m^3
Slovakia OEL - TWA	6 mg/m^3
Spain OEL - TWA	10 mg/m^3

Exposure Controls

Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.
Hands:	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)
Eyes:	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablets	**Color:**	Cream, Peach Gold or Light blue
Odor:	No data available.	**Odor Threshold:**	No data available.
Molecular Formula:	Mixture	**Molecular Weight:**	Mixture

Solvent Solubility: No data available
Water Solubility: No data available
pH: No data available.
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)
Lactose NF, monohydrate
No data available
Conjugated estrogens
No data available
Methylcellulose
No data available
Medroxyprogesterone acetate
No data available
Hydroxypropyl methylcellulose
No data available
Magnesium stearate
No data available
Polyethylene glycol
No data available
Hydroxypropyl cellulose
No data available
Povidone
No data available
Calcium sulfate
No data available
Sucrose
No data available
Glyceryl oleate
No data available
Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammablity:
Autoignition Temperature (Solid) (°C): No data available
Flammability (Solids): No data available

Flash Point (Liquid) (°C):	No data available
Upper Explosive Limits (Liquid) (% by Vol.):	No data available
Lower Explosive Limits (Liquid) (% by Vol.):	No data available

10. STABILITY AND REACTIVITY

Reactivity:	No data available
Chemical Stability:	Stable under normal conditions of use.
Possibility of Hazardous Reactions	
Oxidizing Properties:	No data available
Conditions to Avoid:	Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products:	No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:	The information included in this section describes the potential hazards of the individual ingredients.
Long Term:	Repeat-dose studies in animals have shown a potential to cause adverse effects on reproductive system, the developing fetus. Occupational studies have shown that males working with estrogen-like compounds have shown clinical signs of hyperestrogenism including enlarged breasts and milk secretion. Loss of libido, breast tenderness, and changes in sex hormone levels have also occurred. Occupational exposure in females has resulted in menstrual irregularities (breakthrough bleeding, menstrual flow changes, spotting and amenorrhea).
Known Clinical Effects:	Clinical use of this drug has caused effects on cardiovascular system, menstrual irregularities, lack of menstrual periods (amenorrhea), changes in cervical erosion and secretion, breast enlargement, breast pain, breast development in males (gynecomastia), nausea, vomiting, abdominal cramping, weight changes, fluid retention, changes in sexual desire (libido), loss of hair, mental depression.

Acute Toxicity: (Species, Route, End Point, Dose)

Conjugated estrogens
Rat IP LD50 325 mg/kg
Mouse IV LD50 1740mg/kg
Rat Oral LD50 > 5000mg/kg

Medroxyprogesterone acetate
Rat Oral LD50 > 6,400 mg/kg
Mouse Para-periosteal LD50 376mg/kg
Rat Intraperitoneal LD50 > 400mg/kg
Rat Subcutaneous LD50 > 8000mg/kg

Hydroxypropyl methylcellulose
Rat Oral LD50 > 10,000 mg/kg

Magnesium stearate
Rat Oral LD50 > 2000 mg/kg
Rat Inhalation LC50 > 2000 mg/m^3

11. TOXICOLOGICAL INFORMATION

Povidone
Rat Oral LD50 100 g/kg

Sucrose
Rat Oral LD 50 29,700 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Conjugated estrogens
Eye Irritation Rabbit Severe

Medroxyprogesterone acetate
Eye Irritation Rabbit Non-irritating
Skin Irritation Rabbit Mild

Polyethylene glycol
Eye Irritation Rabbit Mild
Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Medroxyprogesterone acetate
10 Year(s) Monkey Intramuscular3 mg/kg LOAEL Reproductive system
18 Month(s) Mouse Intramuscular 200 mg/kg NOAEL None identified
24 Month(s) Rat Intramuscular 200 mg/kg NOAEL None identified

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Conjugated estrogens
Embryo / Fetal Development Rat Subcutaneous7 mg/kg/day LOAEL Embryotoxicity, Fetotoxicity

Medroxyprogesterone acetate
Embryo / Fetal Development Rat Intramuscular3 mg/kg LOAEL Embryotoxicity, Not teratogenic
Embryo / Fetal Development Monkey Intramuscular 25 mg/kg LOAEL Developmental toxicity
Embryo / Fetal Development Rabbit Intramuscular 1 mg/kg LOAEL Developmental toxicity
Embryo / Fetal Development Rat Subcutaneous 1 mg/kg LOAEL Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Medroxyprogesterone acetate
Bacterial Mutagenicity (Ames) *Salmonella* Negative
Micronucleus Mouse Negative
Chromosome Aberration Rodent germ cell Positive
Sister Chromatid Exchange Rodent Lymphocytes Positive

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

11. TOXICOLOGICAL INFORMATION

Medroxyprogesterone acetate

18 Month(s)	Mouse	Intramuscular	200	mg/kg/month		Not carcinogenic
24 Month(s)	Rat	Intramuscular	200	mg/kg/month		Not carcinogenic
18 Month(s)	Dog	Intramuscular	0.2	mg/kg	LOEL	Benign tumors
40 Month(s)	Dog	Intramuscular	0.3	mg/kg	NOAEL	Tumors, Mammary gland

Carcinogen Status: See below

Conjugated estrogens
IARC: Group 1
NTP: Listed

Medroxyprogesterone acetate
IARC: Group 2B (Possibly Carcinogenic to Humans)

Povidone
IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Calcium sulfate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-900-3

Povidone

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Tricalcium Phosphate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-840-8

Ethyl Acrylate and Methyl Methacrylate Copolymer Dispersion - NF

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Glyceryl oleate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	247-038-6

Conjugated estrogens

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen, initial date 2/27/87; developmental. initial date 4/1/90
EU EINECS/ELINCS List	235-199-5

Hydroxypropyl cellulose

CERCLA/SARA 313 Emission reporting	Not Listed

15. REGULATORY INFORMATION

California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Hydroxypropyl methylcellulose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	Not Listed

Lactose NF, monohydrate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Magnesium stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3

Medroxyprogesterone acetate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen 1/1/1990 developmental toxicity 4/1/1990
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-757-9

Methylcellulose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Microcrystalline cellulose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-674-9

Polyethylene glycol

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed

15. REGULATORY INFORMATION

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 2 Schedule 3
EU EINECS/ELINCS List	Not Listed

Sucrose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-334-9

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Carcinogenicity-Cat.1A; H350 - May cause cancer
Reproductive toxicity-Cat.1A; H360FD - May damage fertility. May damage the unborn child.

Data Sources:	Pfizer proprietary drug development information. Safety data sheets for individual ingredients. Publicly available toxicity information.
Reasons for Revision:	Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 8 - Exposure Controls / Personal Protection.
Revision date:	05-Feb-2018
	Product Stewardship Hazard Communication
Prepared by:	Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet